• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Broadens Criteria for Inclusion of Vulnerable Patients in Cancer Trials

FDA Broadens Criteria for Inclusion of Vulnerable Patients in Cancer Trials

July 13, 2020

Trials of oncology treatments should extend their inclusion criteria to encompass more vulnerable patient populations, the FDA says in four guidances it finalized last week.

Released as drafts in March 2019, the four guidances advise sponsors on inclusion criteria for pediatric patients, patients with brain metastases, those with organ dysfunction or other prior malignancies, and HIV and hepatitis patients (CenterWatch Weekly, March 18, 2019). The final documents are virtually unchanged from their drafts.

In addition to addressing pediatric inclusion in cancer trials, the FDA released a draft guidance in late June to help sponsors design pediatric trials of anti-infective drugs. Sponsors may extrapolate efficacy results from adult studies to use in pediatric studies, the draft guidance says, but still will need to gather safety and pharmacokinetics data to demonstrate that the proposed dosing regimen produces similar exposures in children and adults. Comments on the draft guidance are due by Aug. 29.

To read the guidance on inclusion of HIV and hepatitis patients in cancer trials, click here: https://bit.ly/2AMuQsm.

To read the guidance on including patients with organ dysfunction, click here: https://bit.ly/2ZWLUV7.

To read the guidance on brain metastases, click here: https://bit.ly/2DpblXK.

To read the guidance on including pediatric patients in cancer trials, click here: https://bit.ly/38VWikh.

To read the draft guidance on pediatric trials of anti-infective drugs, click here: https://bit.ly/3iTTdFZ.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing